229 related articles for article (PubMed ID: 31209806)
1. KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell Lung Cancer.
Lei L; Jiang ZM; Li CH; Lu HY
Curr Med Sci; 2019 Jun; 39(3):379-384. PubMed ID: 31209806
[TBL] [Abstract][Full Text] [Related]
2. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
3. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
[TBL] [Abstract][Full Text] [Related]
4. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
5. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
7. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
Bhaumik S; Ahmad F; Das BR
Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
[TBL] [Abstract][Full Text] [Related]
9. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
[TBL] [Abstract][Full Text] [Related]
11. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
[TBL] [Abstract][Full Text] [Related]
14. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.
Abdelraouf F; Sharp A; Maurya M; Mair D; Wotherspoon A; Leary A; Gonzalez de Castro D; Bhosle J; Nassef A; Gaafar T; Popat S; Yap TA; O'Brien M
BMC Res Notes; 2015 Nov; 8():688. PubMed ID: 26581482
[TBL] [Abstract][Full Text] [Related]
15. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
[TBL] [Abstract][Full Text] [Related]
16. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.
Bordi P; Tiseo M; Barbieri F; Bavieri M; Sartori G; Marchetti A; Buttitta F; Bortesi B; Ambrosini-Spaltro A; Gnetti L; Silini EM; Ardizzoni A; Rossi G
Lung Cancer; 2014 Dec; 86(3):324-8. PubMed ID: 25453846
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.
Teng HW; Wang HW; Chen WM; Chao TC; Hsieh YY; Hsih CH; Tzeng CH; Chen PC; Yen CC
J Surg Oncol; 2011 Jun; 103(8):773-81. PubMed ID: 21240992
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
19. Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.
Qiao M; Hu G
Tumour Biol; 2015 Sep; 36(10):7493-9. PubMed ID: 25910706
[TBL] [Abstract][Full Text] [Related]
20. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
Sun JM; Choi YL; Ji JH; Ahn JS; Kim KM; Han J; Ahn MJ; Park K
Ann Oncol; 2015 Jan; 26(1):161-166. PubMed ID: 25355724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
